Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Santiago Ponce Aix"'
Autor:
Rafal Dziadziuszko, Nir Peled, Tony Mok, Solange Peters, Santiago Ponce Aix, Jorge Alatorre-Alexander, Brian D. Vicuna, Margaret Maclennan, Vijay Bhagawati-Prasad, Sarah M. Shagan, Erica Schleifman, Thorsten Ruf, Michael S. Mathisen, Shirish M. Gadgeel
Publikováno v:
Contemporary Oncology, Vol 27, Iss 4, Pp 217-223 (2024)
Externí odkaz:
https://doaj.org/article/de66fd03358a49bbbdeaeff487884027
Autor:
Ernest Nadal, Mansoor Saleh, Santiago Ponce Aix, Maria Ochoa-de-Olza, Sandip Pravin Patel, Scott Antonia, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Shawn T. Estrem, Jiangang Liu, Emin Avsar, Wen Hong Lin, Karim A. Benhadji, Leena Gandhi, Susan C. Guba, Inmaculada Ales Diaz
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background In this phase Ib/II open-label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with recurrent/refractory non-small cell lung cancer (NSCLC) using galunisertib with nivolu
Externí odkaz:
https://doaj.org/article/f152b1db103e441ba5117026cc7aba88
Autor:
Daneng Li, Yohann Loriot, Adam M. Burgoyne, James M. Cleary, Armando Santoro, Daniel Lin, Santiago Ponce Aix, Ignacio Garrido-Laguna, Ramu Sudhagoni, Xiang Guo, Svetlana Andrianova, Scott Paulson
Publikováno v:
EClinicalMedicine, Vol 67, Iss , Pp 102376- (2024)
Summary: Background: Cabozantinib is approved for previously treated advanced hepatocellular carcinoma (aHCC) and has been investigated in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ). Atezolizumab plus bevacizumab is approv
Externí odkaz:
https://doaj.org/article/4755d3d913804c63b46661b4dce5ecba
Autor:
Zoran Andric, MD, Gabriella Gálffy, MD, Manuel Cobo Dols, MD, Barna Szima, MD, Goran Stojanovic, MD, Marina Petrovic, MD, Enriqueta Felip, MD, David Vicente Baz, MD, Santiago Ponce Aix, MD, Oscar Juan-Vidal, MD, Zsuzsanna Szalai, MD, Gyorgy Losonczy, MD, Antonio Calles Blanco, MD, Reyes Bernabe, MD, Gema García Ledo, MD, Andrés Aguilar Hernández, MD, Klaus Duecker, PhD, Dongli Zhou, PhD, Andreas Schroeder, MD, Guelseren Guezel, MD, Fortunato Ciardiello, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100461- (2023)
Introduction: We present the results of a phase 2a trial of first-line avelumab (anti–programmed death-ligand 1 antibody) plus cetuximab (anti–EGFR antibody) in patients with advanced squamous NSCLC. Methods: Patients with recurrent or metastatic
Externí odkaz:
https://doaj.org/article/283d0b24db6b460b8d6628f029ba7cc0
Autor:
Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Lukasz Kuryk, Nicolas Isambert, Susana Cedres, Charles Ricordel, Santiago Ponce Aix, Anne-Sophie Moller, Sylvia Vetrhus
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/7b6dc7621b064d579ed8757704182e8d
Autor:
Luis Paz-Ares, Santiago Ponce Aix, Alejandro Navarro, Reyes Bernabe, Maria Eugenia Olmedo, Trigo Jose Manuel, Jon Zugazagoitia Fraile
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/b9bdce9175d74090a82d14e103d95ea2
Autor:
Andrés Cervantes, Victor Moreno, Maria Jure-Kunkel, Suresh Ramalingam, Emiliano Calvo, Patricia LoRusso, Brandon Higgs, Suzana Couto, Nora Pencheva, Santiago Ponce Aix, Daniel Cho, Alexander Muik, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Elena Garralda, Ulf Forssmann, Eleni Lagkadinou, José Trigo Pérez, Muhammad Furqan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/360983e5b17a4e2ba0207acb0fe600ea
Autor:
Fernando López-Ríos, Luis Paz-Ares, Pilar Garrido, Eva M Garrido-Martin, Jose Palacios, Elena Sanchez, Ana Belén Enguita, Javier Ramos-Paradas, Susana Hernández-Prieto, David Lora, Aranzazu Rosado, Tamara Caniego-Casas, Nuria Carrizo, María Teresa Muñoz-Jimenez, Borja Rodriguez, Urbicio Perez-Gonzalez, David Gómez-Sánchez, Irene Ferrer, Santiago Ponce Aix, Ángel Nuñez Buiza
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background Tumor mutational burden (TMB) is a recently proposed predictive biomarker for immunotherapy in solid tumors, including non-small cell lung cancer (NSCLC). Available assays for TMB determination differ in horizontal coverage, gene content a
Externí odkaz:
https://doaj.org/article/a0e4de9a317e425992c6330eeb6a0581
Autor:
Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, Pieter E. Postmus, Jaafar Bennouna, Jürgen R. Fischer, Oscar Juan-Vidal, David J. Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin Reck, Denis Talbot, Ramaswamy Govindan, Teng Jin Ong
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
Background: The standard therapy for advanced stage non-small cell lung cancer (NSCLC) with no actionable gene alterations is a platinum-based chemotherapy doublet and immune checkpoint blocker (ICB), either concurrently or sequentially, followed by
Externí odkaz:
https://doaj.org/article/559690e73ee44470a728f1e9dd145ed5
Autor:
Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Lukasz Kuryk, Nicolas Isambert, Susana Cedres, Xavier Serres, Charles Ricordel, Santiago Ponce Aix, Anne-Sophie Moller, Sylvia Vetrhus
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/f73b789c28e84aa895fb38bc8393d2d1